Newsletter | January 25, 2024

01.25.24 -- Formycon Ranibizumab Biosimilar Achieved 38% Market Share In The U.S. In Dec 2023


Measurement System Analysis Using Continuous Gage R&R Studies, Part 3

This is the third article in a series of three articles. It continues the discussion of measurement system analysis using continuous gage R&D studies by sharing a generic example using Minitab. Study setup, the role of the study director, analysis, and case studies are examined.


Reliable Components For The Life Cycle Of Your Injectable Drug Product

As drug products increase in complexity, become more specialized, and trend toward self-administration, it is more important than ever to have a reliable drug closure system.


Samsung Bioepis Releases First Quarter 2024 U.S. Biosimilar Market Report

Formycon Ranibizumab Biosimilar FYB201/CIMERLI Achieved A Market Share Of 38% In The U.S. In Dec 2023

Goodwin Releases Update To Its Comprehensive Guide To Biosimilars Litigation & Regulation In The U.S.

Boan Biotech Obtains ANVISA GMP Certification

First Subject Dosed For Phase 1 Clinical Trial Of Henlius’ Ipilimumab Biosimilar HLX13


A Gloveless Aseptic Filling System For Vials, Syringes, And Cartridges